Stockscreener 앱 받기
19.98
1.77%
-0.36
시간 외 거래:
19.98
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Fierce Biotech Layoff Tracker 2025: Unity lays off entire workforce; Mammoth lets go of 24 staffers - Fierce Biotech
APELLIS PHARMACEUTICALS, INC. (NASDAQ: APLS) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - Louisiana First News
Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results - The Manila Times
Apellis Pharmaceuticals to Present Q1 2025 Results: Complement Medicine Leader's Financial Update - Stock Titan
Apellis (APLS) Receives Overweight Rating and Positive Outlook f - GuruFocus
(APLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Cantor Fitzgerald Initiates Coverage of Apellis Pharmaceuticals (APLS) with Overweight Recommendation - MSN
Is Apellis Pharmaceuticals, Inc. (APLS) the Best Oversold NASDAQ Stock to Buy Right Now? - Insider Monkey
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals - Nasdaq
Apellis stock touches 52-week low at $17 amid market challenges - Investing.com Australia
Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Intermediate AMD Market Insights: Key Growth Drivers, Future - openPR.com
11 Best Guru Stocks to Buy According to Wall Street Analysts - Insider Monkey
Craig Wheeler joins Apellis board, brings biopharma expertise By Investing.com - Investing.com South Africa
RBC Capital Lowers Price Target on Apellis (APLS) Amid Market Su - GuruFocus
Craig Wheeler to Join Apellis Board of Directors - citybiz
Apellis Pharmaceuticals appoints new board member - Investing.com Australia
Apellis Pharmaceuticals appoints new board member By Investing.com - Investing.com South Africa
Apellis Announces Craig Wheeler To Join The Board Of Directors - marketscreener.com
Craig Wheeler joins Apellis board, brings biopharma expertise - Investing.com Australia
Apellis Pharmaceuticals (APLS) Welcomes Craig Wheeler to Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors | APLS Stock News - GuruFocus
Apellis Announces Craig Wheeler to Join the Board of Directors - The Manila Times
RBC Cuts Price Target on Apellis Pharmaceuticals to $21 From $24, Keeps Sector Perform Rating - marketscreener.com
Former Momenta CEO Who Led $13.4B Johnson & Johnson Deal Takes Strategic Role at Apellis - Stock Titan
Apellis Announces Craig Wheeler to Join the Board of Directors | - GuruFocus
Apellis Pharmaceuticals (APLS) Target Price Reduced by BofA Ahead of Earnings | APLS Stock News - GuruFocus
BofA Adjusts Price Target on Apellis Pharmaceuticals to $41 From $44, Keeps Buy Rating - marketscreener.com
Geographic Atrophy Therapeutics Market Size in 7MM is expected - openPR.com
The Market Doesn't Like What It Sees From Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues Yet As Shares Tumble 26% - simplywall.st
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges - Investing.com Canada
Apellis Pharma stock hits 52-week low at $21.66 amid market challenges By Investing.com - Investing.com South Africa
0.39%
3.66%
자본화:
|
볼륨(24시간):